Godavari Drugs Ltd. (BSE: 530317) is a Secunderabad, Telangana-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹135 Cr, it ranks #3,005 by market cap among the 6,137 Indian listed companies on FinBizNet, and #64 of 86 in Medicinal Chemicals and Botanical Products. At ₹120.50 (as of 25 Oct 2026), the share price is 16.5% below its 52-week high of ₹144.35 and 72.9% above its 52-week low of ₹69.70. The share price is up 48.5% over one year and up 1.8% over three months.
| Current Price | ₹120.50 |
|---|---|
| Market Cap | ₹135 Cr |
| BSE Code | 530317 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 23.1 |
| Return on Equity | 6.87% |
| Return on Assets | 3.10% |
| 52-Week Range | ₹69.70 – ₹144.35 |
| 1-Year Price Change | +48.5% |
| 3-Month Price Change | +1.8% |
| Beta (1Y) | 0.41 |
| Headquarters | Secunderabad, Telangana |
| Website | godavaridrugs.com |
| Revenue | ₹28 Cr |
|---|---|
| Net Profit | ₹1 Cr |
| Net Margin | 4.0% |
| EPS (Basic) | ₹1.10 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Godavari Drugs Limited manufactures and sells active pharmaceutical ingredients (APIs), drug intermediaries, and fine chemicals in India. The company offers APIs, including ciprofloxacin HCl, ciprofloxacin lactate, ciprofloxacin betaine, mefenamic acid, enrofloxacin, and elthambutoal HCI; and intermediaries, such as A D lactone for spironolactone and 6 mercaptopurine for azathioprine. It also provides loan licenses and contract manufacturing services for APIs and drug intermediates. The company serves the life science industry. Godavari Drugs Limited was incorporated in 1987 and is based in Secunderabad, India.
1. Pharmaceuticals-This segment manufactures active pharmaceutical ingredients and its intermediates.
1. Manufacture and Sale of Active Pharmaceutical Ingredients (API) and its intermediates-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,21,995 Cr | 36.4 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,020 Cr | 22.2 | 18.32% | ₹8,017 Cr | +14.7% |
| Laurus Labs Ltd | ₹1,11,310 Cr | 125.3 | 17.74% | ₹2,026 Cr | +125.7% |
| Cipla Limited | ₹1,07,048 Cr | 27.6 | 11.74% | ₹7,119 Cr | -14.7% |
| Dr.Reddys Lab | ₹1,02,611 Cr | 24.1 | 11.52% | ₹8,698 Cr | -0.9% |
| Aurobindo Pharma Ltd. | ₹95,910 Cr | 26.8 | 9.93% | ₹9,150 Cr | +41.7% |
| Mankind Pharma | ₹93,977 Cr | 48.7 | 12.45% | ₹4,031 Cr | -9.9% |
| Lupin Ltd | ₹89,426 Cr | 16.6 | 26.91% | ₹8,277 Cr | -1.1% |
| Godavari Drugs Ltd. | ₹135 Cr | 23.1 | 6.87% | ₹28 Cr | +48.5% |
Listed by market capitalisation. Ratios are shown for context only.
Godavari Drugs Ltd. is trading at ₹120.50, with a market capitalisation of ₹135 Cr.
Godavari Drugs Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Godavari Drugs Ltd. has a P/E of 23.1 and a return on equity of 6.87%.
Godavari Drugs Ltd. is listed on the BSE under the scrip code 530317.
Godavari Drugs Ltd.'s share price is up 48.5% over one year and up 1.8% over three months. Its 52-week range is ₹69.70 to ₹144.35.
In Q1 FY27, Godavari Drugs Ltd. reported revenue of ₹28 Cr and net profit of ₹1 Cr, with basic EPS of ₹1.1 (standalone, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.